Inflammation News and Research

RSS

Researchers explore optimal induction therapies for managing blood cancer

There have been significant scientific advances in the field of blood cancers, and leading experts continue to gain a better understanding of how certain diseases progress in order to discover new treatment options and provide patients with the best care.

7 Dec 2009

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

Allos Therapeutics, Inc. today reported new analyses of data from the Company’s pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

7 Dec 2009

New approach to protein misfolding may lead to novel therapies for a number of diseases

In an encouraging new development, a team led by Scripps Research Institute scientists has restored partial function to lung cells collected from patients with cystic fibrosis. While there is still much work to be done before the therapy can be tested in humans, the discovery opens the door to a new class of therapies for this and a host of other chronic diseases.

7 Dec 2009

Researchers discover two new metabolic pathways

Case Western Reserve University researchers, from the School of Medicine's Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abuse, known as 4-hydroxyacids, are metabolized.

5 Dec 2009

Statins may protect against GVHD complications

Cholesterol-lowering drugs known as statins are among the most prescribed medicines in the U.S. Now a new study by researchers at Fred Hutchinson Cancer Research Center indicates that statins may protect stem cell transplant patients from one of the most serious complications of the life-saving cancer therapy: graft-versus-host disease, or GVHD.

5 Dec 2009

New Center for Digestive Care to care for all aspects of digestive disease

The Center for Digestive Care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center has been established with a mission to provide high-quality patient care, research and education for all aspects of digestive disease.

4 Dec 2009

Two antimicrobial drug developing companies evaluate new approach for treating bacterial infections

Chaperone Technologies, Inc. and MerLion Pharmaceuticals Pte Ltd., both privately-held companies developing new antimicrobial drugs, announced today that they are together evaluating a unique approach for the treatment of resistant and life-threatening bacterial infections.

4 Dec 2009

Last patient visit complete in VIA Pharmaceuticals' Phase 2 FDG-PET trial

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has completed the last patient visit in its Phase 2 FDG-PET clinical trial of VIA-2291.

3 Dec 2009

Initial positive data from Amira Pharmaceuticals' Phase 1 clinical study of AM461 DP2 antagonist

Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM461, the Company's second oral selective antagonist of the DP2 (also known as CRTH2) receptor.

3 Dec 2009

Don't stop dieting during the holiday season

As Americans gear up for the holiday season this month, Dr. Sasson Moulavi, a Board Certified Bariatric Physician, cautions that overweight and obese patients not give in to temptation and forget their dieting. Rather, Dr. Sass, founder of the Smart for Life(R) Cookie Diet, recommends alternative behavior for a positive outcome when it is time to ring in the New Year.

3 Dec 2009

Positive results from NanoBio's recombinant H5N1 flu antigen-nanoemulsion vaccine combination study

NanoBio Corporation today announced positive results from studies in mice in which immune responses were evaluated following administration of 5µg doses of recombinant H5N1 pandemic flu antigen combined with the company’s novel nanoemulsion vaccine. These studies are unique because the adjuvant was administered for the first time by subcutaneous (SC) and intramuscular (IM) injections.

3 Dec 2009

PEG polymer may prevent GI injury during cancer radiotherapy

A non-absorbed, oral co-polymer therapy under development by Midway Pharmaceuticals demonstrated the ability to protect against damage to healthy gastrointestinal tissues and to prevent lethal bacterial infections in animal models of radiation damage.

3 Dec 2009

Lunasin may have important health benefits, two new studies report

Two new University of Illinois studies report that lunasin, a soy peptide often discarded in the waste streams of soy-processing plants, may have important health benefits that include fighting leukemia and blocking the inflammation that accompanies such chronic health conditions as diabetes, heart disease, and stroke.

3 Dec 2009

NHLBI awards new federal grant to improve the quality of stored transfusion blood

A new, $2.8 million, four-year federal grant will support researchers at the University of Pittsburgh School of Medicine and their collaborators at Wake Forest University as they study why the quality of stored transfusion blood degrades over time and how to address the problem.

3 Dec 2009

Research study compares genetic make-up of humans and primates

In spite of their genetic similarity to humans, chimpanzees and great apes have maximum lifespans that rarely exceed 50 years. The difference, explains USC Davis School of Gerontology Professor Caleb Finch, is that as humans evolved genes that enabled them to better adjust to levels of infection and inflammation and to the high cholesterol levels of their meat rich diets.

3 Dec 2009

Respiratory syncytial virus, the most common cause of pneumonia in children

RSV is a respiratory virus that infects the lungs and breathing passages. While most healthy people recover from RSV infection, it can be severe in infants. According to the United States Centers for Disease Control and Prevention (CDC), RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under 1 year of age in the nation.

3 Dec 2009

University of Pittsburgh's McGowan Institute for Regenerative Medicine awarded IBM SUR grant

The University of Pittsburgh's McGowan Institute for Regenerative Medicine, which connects scientists who work on tissue engineering, cell therapies, artificial organs and biodevices, has been awarded a Shared University Research (SUR) Award from IBM ( IBM). The IBM SUR Award will provide IBM computer hardware, software and services to Pitt for its cutting-edge "in silico" biological research, which uses computer simulations to explore biological pathways and test therapeutic interventions.

2 Dec 2009

New approach to identify molecules that prevent immune cells from attacking body

A study led by a Scripps Research Institute scientist describes a new, highly pragmatic approach to the identification of molecules that prevent a specific type of immune cells from attacking their host. The findings add a powerful new tool to the ongoing search for potential treatments for autoimmune diseases, such as multiple sclerosis (MS), as well as blood cancers, such as myeloid leukemia.

2 Dec 2009

Antipsychotic medications increase the levels of inflammation markers, find researchers

Overall, antipsychotic medications are reasonably effective, and fairly well tolerated treatments for mood and psychotic disorders. However, treatment with a number of antipsychotic medications is associated with weight gain, and for some, hyperglycemia and hyperlipidemia.

2 Dec 2009

FDA grants approval for Dyax' KALBITOR for treating HAE patients

Dyax Corp. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for KALBITOR® (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.

2 Dec 2009

Inflammation News and Research

Researchers explore optimal induction therapies for managing blood cancer

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

New approach to protein misfolding may lead to novel therapies for a number of diseases

Researchers discover two new metabolic pathways

Statins may protect against GVHD complications

New Center for Digestive Care to care for all aspects of digestive disease

Two antimicrobial drug developing companies evaluate new approach for treating bacterial infections

Last patient visit complete in VIA Pharmaceuticals' Phase 2 FDG-PET trial

Initial positive data from Amira Pharmaceuticals' Phase 1 clinical study of AM461 DP2 antagonist

Don't stop dieting during the holiday season

Positive results from NanoBio's recombinant H5N1 flu antigen-nanoemulsion vaccine combination study

PEG polymer may prevent GI injury during cancer radiotherapy

Lunasin may have important health benefits, two new studies report

NHLBI awards new federal grant to improve the quality of stored transfusion blood

Research study compares genetic make-up of humans and primates

Respiratory syncytial virus, the most common cause of pneumonia in children

University of Pittsburgh's McGowan Institute for Regenerative Medicine awarded IBM SUR grant

New approach to identify molecules that prevent immune cells from attacking body

Antipsychotic medications increase the levels of inflammation markers, find researchers

FDA grants approval for Dyax' KALBITOR for treating HAE patients

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News